| Theme | Antiplatelet and Anticoagulation Therapy in Patients with Chronic Kidney Disease -- up to date of evidence | |
|---|---|---|
| Title | The anticoagulation and antiplatelet therapies for heart diseases in patients with chronic kidney disease | |
| Publish Date | 2012/07 | |
| Author | Masato Nishimura | Cardiovascular Division, Toujinkai Hospital |
| [ Summary ] | A common aim of anticoagulation therapy for patients with heart diseases and chronic kidney disease is to prevent cardiac thrombosis associated with chronic atrial fibrillation or artifi cial valve replacement. Anticoagulation therapy after artificial valve replacement therapy should be done strictly for patients in PT-INR ranges between 2 and 3. Anticoagulation therapy should be reduced when PT-INR rates are below two. Reduced treatment should be implemented for patients with chronic atrial fibrillation to avoid bleeding events. Aspirin and clopidogrel, which is a thienopyridine class antiplatelet agent, are used to inhibit blood clots after coronary stent implantation. Long-term administration of oral low-dose aspirin and clopidogrel is desirable to inhibit coronary in-stent thrombosis. | |